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Abstract
The link between magnesium (Mg) deficiency and type 2 diabetes 
mellitus is well known. Type 2 diabetes is frequently associated 
with both extracellular and intracellular Mg deficits. A chronic 
latent Mg deficit or an overt clinical hypomagnesaemia is common 
in subjects with type 2 diabetes, especially in those with poorly 
controlled glycemic profiles. Insulin and glucose are important 
regulators of Mg metabolism. Intracellular Mg plays a key role in 
regulating insulin action, insulin-mediated-glucose-uptake and 
vascular tone. Reduced intracellular Mg concentrations result in 
a defective tyrosine-kinase activity, postreceptorial impairment 
in insulin action and worsening of insulin resistance in diabetic 
patients. A low Mg intake and an increased Mg urinary loss appear 
the most important mechanisms that may favor Mg depletion in 
patients with type 2 diabetes. Low dietary Mg intake has been 
related to the development of type 2 diabetes and metabolic 
syndrome.  Benefits of Mg supplementation on metabolic profile 
in diabetic subjects have been found in most, but not all clinical 
studies and larger prospective studies are needed to support the 
potential role of dietary Mg supplementation as a possible public 
health strategy in diabetes risk.
The objective of this review is to revise current evidences on the 
mechanisms of Mg deficiency in diabetes mellitus type 2 and on 
the possible role of Mg supplementation in the prevention and 
management of the disease.
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those with poorly controlled glycemic profiles, with longer duration 
of the disease and with the presence of micro-macrovascular chronic 
complications [2-6].
The definition of Mg deficiency seems simpler than it is, 
primarily because accurate clinical tests for the assessment of Mg 
status are lacking. Patients are considered frank hypomagnesaemic 
with serum Mg concentrations ≤0.61mmol/L or 1.5mg/dL [7-9]. 
Mg concentrations ≤0.75mmol/L or 1.8mg/dL may be considered a 
preclinical hypomagnesaemia  [10,11].
Because of the lack of sensitivity of total serum Mg, a Mg 
deficiency can be present without hypomagnesaemia. However, 
hypomagnesaemia is usually indicative of a systemic Mg deficit. 
Depletion in intracellular and serum ionized Mg can be found in 
many subjects with total serum Mg still in the normal range [12]. 
We have recently confirmed that diabetic older patients are more 
prone to hypomagnesaemia; this condition being closely related 
with metabolic control as measured by glycated hemoglobin even 
after adjustment for relevant confounders. Ionized Mg may help to 
identify older diabetic adults with low concentrations of blood Mg 
that are not evident with the only measurement of total Mg [12].
At the cellular level, cytosolic free Mg levels are consistently 
reduced in subjects with type 2 diabetes mellitus, when compared 
with nondiabetic subjects [1,13,14]. An impairment of cellular Mg 
uptake mechanism, and a the decrease in the cellular ATP level, may 
contribute, at least in part, to explain the decrease in cellular Mg 
content observed under diabetic conditions [15]. The relationship 
between intra-cellular Mg and ATP concentration is rather complex. 
The decrease in cellular ATP might partially explain the decrease 
in cellular Mg. Otherwise, a decrease in cellular ATP leads to a 
decreased binding of Mg to ATP in the formation of MgATP which 
might increase the intracellular Mg concentration.
The objective of this review is to revise current evidences on 
the mechanisms of Mg deficiency in diabetes mellitus type 2 and 
on the possible role of Mg supplementation in the prevention and 
management of the disease.
Mechanisms of Mg Deficiency in Diabetes
A low Mg intake and an increased Mg urinary loss appears the 
most important mechanisms that may favor Mg depletion in patients 
Introduction
Magnesium (Mg) is the fourth most abundant mineral present 
in the human body and the second intracellular cation in living 
cells after potassium. Most Mg located in the human adult’s body 
is distributed in the intracellular compartment (99%), and only 1% 
in the extracellular fluid [1].  The link between Mg deficiency and 
type 2 diabetes mellitus is well known. Type 2 diabetes is frequently 
associated with both extracellular and intracellular Mg depletion. 
Several epidemiologic studies have recognized a high prevalence 
of hypomagnesaemia in subjects with type 2 diabetes, especially in 
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with type 2 diabetes, while Mg absorption and retention of dietary Mg 
seems not to be impaired in patients with type 2 diabetes [1,16,17]. 
With regard to low Mg intake, changes in dietary habits in the western 
world have resulted in daily Mg intake close to, or even below, the 
recommended daily allowances. The ARIC study demonstrated a 
relationship between serum Mg and the development of diabetes in 
the general population [18]. Diabetes is associated with renal calcium 
and Mg wasting [19-21], but the molecular mechanism(s) of these 
defects are not completely elucidated [22]. Recent findings in obese 
diabetic rats found that TRPM6 was down regulated explaining renal 
Mg wasting [23].  The findings from Mandon, showing a insulin-
induced Mg uptake in the thick ascending loop of Henle may also 
have a role [24], since hyperinsulinemia and insulin resistance 
may lead to a decreased Mg uptake, and an increase Mg excretion. 
Hyperglycemia also contributes to an increased urinary Mg wasting 
contributing to Mg depletion. Plasma Mg levels were found inversely 
correlated with the urinary Mg excretion rate and with fasting blood 
glucose values, suggesting that the tubular reabsorption of Mg is 
decreased in presence of severe hyperglycemia [19].
An increased renal Mg transporter abundance was found in 
diabetic rats and may represent a compensatory adaptation for the 
increased load of Mg to the distal tubule. Insulin administration 
completely corrected the hyperglycemia-associated hypercalciuria 
and hypermagnesiuria, and reversed the increase of Mg transporter 
abundance [22]. An improved metabolic control was associated with 
reduced urinary Mg losses [3]. Hyperinsulinemia, which is present 
in insulin resistant states, may contribute per se to the urinary Mg 
depletion, to the reduced sensitivity to insulin, and may itself affect Mg 
transport [20]. Djurhuus in healthy volunteers with hyperinsulinemia 
suggested that in these people is different from hyperinsulinemia in 
people with prediabetes, metabolic syndrome [20,25].
In addition other factors like metabolic acidosis or 
hypoalbuminemia also seem to affect renal Mg wasting in diabetes 
[21]. The use of loop and thiazide diuretics, often prescribed in 
diabetic patients with hypertension and/or cardiovascular diseases, 
also promote Mg wasting.
Mg Deficiency and Insulin Resistance
 Mg deficiency in type 2 diabetes may take the form of a chronic 
latent Mg deficit rather than an overt clinical hypomagnesaemia 
[12], and may have clinical importance because the Mg ion is a 
crucial cofactor for many enzymatic reactions involved in a myriad 
of metabolic processes. The Mg ion plays a key role in the regulation 
of the effects of insulin and insulin-mediated cellular glucose intake. 
Mg is a necessary co-factor in >300 enzymatic reactions that include 
all the enzymes determinant of glycolysis. Intracellular Mg is a critical 
cofactor for enzymes involved in carbohydrate metabolism, and 
specifically in the process of phosphorylation of the tyrosine-kinase of 
the insulin receptor as well as all other protein kinases in the insulin 
signaling, and all ATP and phosphate transfer-associated enzymes, 
such as the CaATPases in the plasma membrane and the endoplasmic 
reticulum [1,26]. 
Mg deficiency may result in disorders of tyrosine kinase 
activity of the insulin receptor, event related to the development of 
post-receptorial insulin resistance and decreased cellular glucose 
utilization, that is, the lower the basal Mg, the greater the amount 
of insulin required to metabolize the same glucose load, indicating 
a decreased insulin sensitivity [17]. Cellular concentrations of Mg 
are in the 100-300nmol/L range, which is close to the dissociation 
constant of many enzymes systems using ATP or phosphate 
transference, confirming the clinical importance of Mg deficiency. A 
deficient Mg status may be a secondary consequence or may precede 
and cause insulin resistance and altered glucose tolerance, and even 
diabetes. Inflammation and oxidative stress have been proposed to be 
a possible link between Mg deficit and insulin resistance/metabolic 
syndrome. Chronic hypomagnesaemia and conditions commonly 
associated with Mg deficiency, such as type 2 diabetes mellitus, 
metabolic syndrome and aging, are associated with increased free 
radical formation and subsequent damage to cellular processes 
[27,28].  Aging is frequently associated with insulin resistance and 
glucose intolerance. A continuous age-dependent fall of intracellular 
Mg levels in peripheral blood cells of healthy elderly subjects 
is present, these alterations being indistinguishable from those 
occurring, independently of age, in essential hypertension or type 2 
diabetes [14,28].
The relevance of altered cellular Mg metabolism to tissutal 
insulin sensitivity suggest a possible role of Mg in contributing to the 
clinical coincidence of Mg depletion to clinical conditions of insulin 
resistance such as hypertension, metabolic syndrome, type 2 diabetes 
as well with the increased incidence of each of these conditions with 
age, a condition itself characterized by a tendency to Mg depletion 
[17].
Altogether, independent to the cause of poor plasma and 
intracellular Mg content, a depletion of Mg seems to contribute to an 
impairment of insulin sensitivity. A deficient Mg status may not just 
be a secondary consequence of type 2 diabetes but may precedes and 
contributes itself to the development of insulin resistance and altered 
glucose tolerance, and even type 2 diabetes. We have suggested a 
role for Mg deficit as a possible unifying mechanism of conditions 
associated to “insulin resistance, including type 2 diabetes mellitus, 
metabolic syndrome, and essential hypertension [1,17]. The Mg 
deficit could precede and cause post-receptorial resistance of insulin 
and alter the glucose tolerance.
Mg Deficiency and Cardio-Metabolic Diseases
It has been suggested that Mg deficiency may be a factor implicated 
in the pathogenesis of diabetes complications. Cellular ionic 
alterations are related to the cardiovascular structural modifications 
often present in diabetes. A significant relation was found between 
fasting levels of intracellular Mg levels and cardiovascular structural 
indices [29]. In type 2 diabetic subjects, even in the absence of 
elevated blood pressure, suppressed intracellular Mg levels are 
associated with cardiac hypertrophy, and specifically with increased 
echocardiographically measured posterior wall thickness and left 
ventricular mass index in both diabetic and/or hypertensive subjects 
[29]. Similarly, aortic distensibility values determined by magnetic 
resonance imaging in normal and hypertensive humans were closely 
and positively related to concomitantly measured levels of cellular 
Mg measured in situ in brain and skeletal muscle tissue by 31P-NMR 
magnetic resonance spectroscopic techniques: the more suppressed 
the intracellular Mg, the stiffer (less distensible) the aorta [30]. Low 
serum Mg concentrations are associated with a high prevalence of 
premature ventricular complexes in obese adults with type 2 diabetes 
[6]. In patients with type 2 diabetes mellitus, low circulating Mg levels 
have been associated also with a more rapid decline of renal function. 
Hypomagnesaemia is currently considered an accurate predictor 
of progression to end stage renal disease and death and in patients 
with type 2 diabetic nephropathy [31-33]. A Mg deficit have been 
associated to cognitive decline [34], multimorbidity [35] and aging 
[28,36].
Dietary Mg Deficiency May Predispose to Insulin 
resistance and Type 2 Diabetes Mellitus
The hypothesis that Mg deficit in the diet would induce and/or 
exacerbate insulin resistance is confirmed by data, both in humans 
and in experimental animals, which have consistently shown dietary 
Mg deficiency is associated to insulin resistance [37-43]. Mg-
deficient diet in sheep cause a significant impairment of insulin-
mediated glucose uptake [38] and Mg supplementation delayed the 
development of diabetes in a rat model of diabetes [39]. Higher Mg 
intake is associated with lower fasting insulin concentrations among 
women without diabetes [40], and a significant negative correlation 
is present between total dietary Mg intake and the insulin responses 
to an oral glucose tolerance test [41]. Rats fed a low Mg diet showed 
a significant increase in blood glucose and triglyceride levels [42]. 
Suarez et al. investigated the effect of dietary-induced Mg deficiency 
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on glucose disposal, glucose-stimulated insulin secretion and insulin 
action on skeletal muscle in rats, which were fed a low Mg-containing 
diet. Mg depletion provoked a deleterious effect on glucose 
metabolism due to an impairment of both insulin secretion and 
action. In rats, maternal Mg restriction induces insulin resistance in 
pups by 6 months of age, whereas additional perinatal Mg deficiency 
impairs glucose tolerance [43]. The insulin resistance observed in 
skeletal muscle of Mg-deficient rats was linked, at least in part, to a 
defective tyrosine kinase activity of insulin receptors [44].
Dietary Mg deficits have also been associated to the development of 
diabetes. Deficiencies of Mg status including both hypomagnesaemia 
and/or reduced dietary Mg intake have been associated with an 
increased risk to develop glucose intolerance and diabetes [18,45-47] 
while an increased Mg intake is associated with a significant decline 
in the incidence of type 2 diabetes [48].
Various epidemiological studies have confirmed a clear and 
direct relationship between the Mg status in the diet, type 2 diabetes 
and metabolic syndrome, suggesting that the higher consumption of 
Mg is related with a reduction of the incidence of these conditions. 
Two meta-analyses of prospective studies concluded that Mg intake is 
inversely associated with type 2 diabetes [49,50]. Mg intake has been 
also strongly and inversely associated with the metabolic syndrome 
[37,51], while hypomagnesaemia has been independently associated 
with the development of impaired glucose tolerance [52]. Increased 
Mg intake is associated with increased insulin sensitivity [53] and a 
decreased risk of developing type 2 diabetes [54,55]. In a prospective 
study of more than 85,000 women, followed for 18 months the relative 
risk of developing type 2 diabetes for women in the highest quintile 
of Mg consumption was 0.68 compared with women in the lowest 
quintile after adjustment for a number of potentially confounding 
variables. A significant inverse association was found between Mg 
intake and diabetes risk [55]. In the Women's Health Study, a cohort 
of 39,345 U.S. women aged ≥45 years with no previous history of 
cardiovascular disease, cancer, or type 2 diabetes was recruited and 
followed for an average of 6 years. A significant inverse association 
was found between Mg intake and the risk of developing type 2 
diabetes, supporting a protective role of higher intake of Mg in 
reducing the risk of developing type 2 diabetes [54].
In a large cohort of young American adults, participating in the 
Coronary Artery Risk Development in Young Adults (CARDIA) 
study, during the 20-year follow-up, Mg intake was inversely 
longitudinally associated with the incidence of diabetes in this young 
American population, after adjustment for potential confounders. 
This inverse association may be explained, at least in part, by the 
inverse correlations of Mg intake with systemic inflammation and 
insulin resistance [56].
Hypomagnesemia has been associated with inflammation and 
increased production of free oxygen radicals [57,58]. Poor Mg 
status may trigger the development of a proinflammatory state 
both by causing excessive production and release of interleukins 
and by elevating circulating concentrations of proinflammatory 
neuropeptides that trigger activation of low-grade chronic 
inflammation [28,59]. Thus, dietary-induced Mg deficiency increases 
thromboxane urinary concentration and enhances angiotensin-
induced aldosterone synthesis. These effects are associated with a 
decrease in insulin action, further confirming that Mg deficiency may 
be a common factor associated with insulin resistance and vascular 
disease [60].
Mg Supplementation in the Prevention and 
Management of Diabetes
The detection and correction of altered Mg status in diabetic 
patients is clinically appropriate, although many physicians tend to 
ignore Mg status. The increased risks to develop glucose intolerance 
and type 2 diabetes mellitus in subjects with dietary and/or serum Mg 
deficits have suggested potential benefits of Mg supplementation in 
persons who have type 2 diabetes or risk factors for diabetes. The use 
of Mg supplements has also been proposed as a potential tool for the 
prevention and the metabolic control of type 2 diabetes [61,62].
Benefits of Mg supplements on glycemic profile in most but not 
all studies explain whether according to meta-analysis a net beneficial 
effect is to be expected. The clinical evidences of a clear effects of 
Mg supplements on the metabolic profile of diabetic subjects are 
controversial, benefits having been found in many [8,61,63,64], but 
not in all clinical studies [65].
While the body of evidence from epidemiological studies 
consistently shows a strong inverse relationship between dietary Mg 
intake and the risk of developing type 2 diabetes mellitus, results 
from clinical trials are scarce and controversial [66]. Still, the risk of 
residual confounding factors in these kinds of analyses deserves to be 
taken into consideration. The hypothesis of a role of supplemental 
Mg in the control of type 2 diabetes still needs to be confirmed by 
specific and well-designed large randomized clinical trials with Mg 
[67,68].
Mg supplementation may improve glycemic concentrations in 
fasting and postprandial states and improves the insulin-mediated 
glucose uptake measured by euglycemic insulin clamp, with a 
significant relationship between the parallel increase in plasma 
and erythrocyte Mg concentration and the progressive increase in 
insulin sensitivity [69]. Mg supplementation was also able to restore 
altered endothelial function in elderly diabetic subjects [70], and was 
suggested to be useful in the treatment of depression in the elderly 
with type 2 diabetes and hypomagnesaemia [71].
Mooren et al. in normomagnesemic insulin resistant subjects, 
Mg improved fasting glycemia [72]. Presumably, the main problem is 
that all RCT were underpowered, partially through overestimation of 
the treatment effect. Differences may be related to the fact that most 
of the existing studies have included a small number of subjects, using 
different Mg doses and different Mg salts.
The available studies have shown that Mg may mediate the 
favorable impact of whole grains on insulin sensitivity cereal on 
insulin sensitivity [73-76]. A recent clinical randomized double-blind 
placebo-controlled trial has shown that oral Mg supplementation 
decreases C-reactive protein levels in subjects with prediabetes and 
frank hypomagnesaemia [77]. In type 2 diabetic patients with clinical 
hypomagnesaemia (index of an already advanced Mg deficit) oral Mg 
supplementation had beneficial effects on fasting and postprandial 
glucose levels and on insulin sensitivity [63]. A small but significant 
beneficial effect of Mg supplements on insulin sensitivity among non-
diabetic, apparently healthy subjects was suggested [8].  Altogether, 
Mg supplementation in diabetic patients (with frank Mg deficiency) 
corrects the deficit in intracellular free Mg levels, improves insulin 
sensitivity, and may protect against diabetic complications. The 
positive effects of a high intake of Mg on systemic inflammation and 
insulin resistance may help to explain at least some of its favorable 
effects.
We suggest that fact that most but not all diabetic subjects have 
a Mg deficiency and that no large clinical trial have been specifically 
focused on subjects with a Mg deficit, diagnosed with an accurate and 
reliable technique, may help to explain the discrepancy between the 
unclear role of supplemental Mg on glycemic control in diabetics, and 
the significant impact on diabetes risk in prospective epidemiologic 
studies.
Differences in baseline Mg status and metabolic control, and age 
of the subjects are other potential factors that may help to explain the 
differences among the studies. Future prospective randomized large 
clinical studies are needed to support the potential role of dietary 
Mg supplementation as a possible public health strategy to reduce 
diabetes risk in the population.
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